Urology patients, like others, have been adversely impacted by the COVID19 crisis with almost all surgery, day case services and outpatients appointments abruptly halted in UHG. Patients with high risk non muscle invasive bladder cancer experience some of the highest rates of cancer recurrence and are at high risk of progression to muscle invasive disease. These patients require frequent, often life long invasive cystoscopic surveillance as well as repeat chemo or immunotherapy bladder instillations. To continue caring for these ‘high risk’ patients, we developed and adapted a series of ‘COVID19’ protocols to enable the ongoing, although limited, delivery of day case and nurse led bladder cancer services with a strong emphasis on risk management and patient safety.